EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Understanding the Modes of Action of β-Ketoiminato Iridium(III) Complexes in Cancer Cells

Tameryn Stringer iD, Büşra Yildirim, Baris Sergi iD, Benjamin J Hofmann iD, Yi-Hsuan Lee, Ceyda Acilan, Rianne M Lord iD

Inorganic Chemistry · 2025

DOI: 10.1021/acs.inorgchem.5c02026 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Inorganic Chemistry, 2025. Verfasst von Tameryn Stringer und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Chemistry, Pharmacy and Pharmacology, University of East Anglia, Norwich, Norfolk NR4 7TJ, United Kingdom. Hauptthemen laut MEDLINE: Iridium, Antineoplastic Agents, Coordination Complexes. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Four new charged iridium(III) 1,2,3,4,5-pentamethylcyclopentadienyl (Cp*) complexes, 1-4, of the type [Cp*Ir(L1-4)(PTA)](PF6) (where L1-4 = functionalized β-ketoiminate ligands and PTA = 1,3,5-triaza-7-phosphaadamantane), have been successfully synthesized and characterized. Single crystal X-ray crystallographic data have been obtained for all compounds and confirm a typical pseudo-octahedral half-sandwich geometry. Cytotoxicity values have been determined against a range of cancerous and noncancerous cell lines and highlight high cytotoxicity and selectivity toward breast cancers. Among these compounds, the unfunctionalized β-ketoiminate Ir(III) complex (1) emerged as the most promising candidate, demonstrating activity that was comparable to or exceeded that of cisplatin, especially after 24 h against the triple-negative MDA-MB-231 cell line. Morphological and molecular analyses confirmed that 1 triggers apoptotic cell death, involving caspase activation and PARP cleavage, which is consistent with its DNA-damaging characteristics, highlighting the future anticancer potential of compound 1.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

IridiumAntineoplastic AgentsCoordination ComplexesHumansDrug Screening Assays, AntitumorCell Line, TumorApoptosisCell ProliferationMolecular StructureStructure-Activity RelationshipCrystallography, X-RayModels, MolecularDose-Response Relationship, Drug

Substanzen

IridiumAntineoplastic AgentsCoordination Complexes

Autor:innen und Institutionen

  • School of Chemistry, Pharmacy and Pharmacology, University of East Anglia, Norwich, Norfolk NR4 7TJ, United Kingdom.
  • School of Science, The University of Waikato, Hamilton 3210, New Zealand.
  • Graduate School of Health Sciences, Koç University, Istanbul 34450, Turkey.
  • Department of Chemistry, University of Warwick, Coventry CV4 7AL, United Kingdom.
  • Koç University Translational Research Center, KUTTAM, Istanbul 34450, Turkey.
  • School of Medicine, Koç University, Sariyer, Istanbul 34450, Turkey.

ORCID-Profile: Tameryn Stringer, Baris Sergi, Benjamin J Hofmann, Rianne M Lord

Förderung

  • Medical Research Council

Zitieren

APA

Stringer, T., Yildirim, B., Sergi, B., Hofmann, B. J., Lee, Y. H., Acilan, C., & Lord, R. M. (2025). Understanding the Modes of Action of β-Ketoiminato Iridium(III) Complexes in Cancer Cells. Inorganic Chemistry. https://doi.org/10.1021/acs.inorgchem.5c02026

Vancouver

Stringer T, Yildirim B, Sergi B, Hofmann BJ, Lee YH, Acilan C, et al. Understanding the Modes of Action of β-Ketoiminato Iridium(III) Complexes in Cancer Cells. Inorganic Chemistry. 2025. doi:10.1021/acs.inorgchem.5c02026

BibTeX
@article{Stringer2025,
  author = {Stringer, Tameryn and Yildirim, Büşra and Sergi, Baris and Hofmann, Benjamin J and Lee, Yi-Hsuan and Acilan, Ceyda and Lord, Rianne M},
  title = {Understanding the Modes of Action of β-Ketoiminato Iridium(III) Complexes in Cancer Cells},
  journal = {Inorganic Chemistry},
  year = {2025},
  doi = {10.1021/acs.inorgchem.5c02026}
}
Kostenlos starten →